Astrazeneca Plc LSE
Stay in step with market opportunities and get insights, actionable trade ideas and dedicated support.
Sort by:
- Newest
- Popular
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q4 preview: Where next for the AstraZeneca share price?
Markets believe AstraZeneca can continue to deliver strong double-digit growth in 2022, but will the pharma giant’s outlook meet expectations this week?
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
Open an account today
Tight spreads from 0.5 pts on FX and 1 pt on indices.
Award-winning platforms with fast and secure execution.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
90 days risk-free trading with £10,000 in virtual funds
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
For further details see our full non-independent research disclaimer and quarterly summary.